When to inject thymosin alpha-1?

Published trials on this site do not establish a time of day for a research vial. The human findings are a 98-person hepatitis B trial (complete virological response at 18 months after a 26-week course) and the TESTS sepsis trial (1,106 adults; 28-day mortality 23.4% versus 24.1% on placebo). Where it is approved as Zadaxin, that country's label sets the protocol. This FAQ does not give a dose, a frequency, or a protocol. Technique and rotation are at /injecting.

Full injecting guide: sites, needles, rotation, safety

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of more absences and national fields. Further harvested questions after the first names-and-absences set: more side effects the citations did not count, compounding formulas this catalogue does not hold, national legal-status fields for compounds that only have those four countries, trial windows rather than an onset clock, and named prescription combinations with no interaction table.